Mucosal Antibody Response to SARS-CoV-2 in Paediatric and Adult Patients: A Longitudinal Study

Overview

Journal Pathogens

Date 2022 Apr 23

PMID 35456072

Authors

Renee W Y Chan

Kate C C Chan

Grace C Y Lui

Joseph G S Tsun

Kathy Y Y Chan

Jasmine S K Yip

Shaojun Liu

Michelle W L Yu

Rita W Y Ng

Kelvin K L Chong

Maggie H Wang

Paul K S Chan

Albert M Li

Hugh Simon Lam

Affiliations

Soon will be listed here.

Abstract

Background: SARS-CoV-2 enters the body through inhalation or self-inoculation to mucosal surfaces. The kinetics of the ocular and nasal mucosal-specific-immunoglobulin A(IgA) responses remain under-studied.

Methods: Conjunctival fluid (CF, = 140) and nasal epithelial lining fluid (NELF, = 424) obtained by paper strips and plasma ( = 153) were collected longitudinally from SARS-CoV-2 paediatric ( = 34) and adult ( = 47) patients. The SARS-CoV-2 spike protein 1(S1)-specific mucosal antibody levels in COVID-19 patients, from hospital admission to six months post-diagnosis, were assessed.

Results: The mucosal antibody was IgA-predominant. In the NELF of asymptomatic paediatric patients, S1-specific IgA was induced as early as the first four days post-diagnosis. Their plasma S1-specific IgG levels were higher than in symptomatic patients in the second week after diagnosis. The IgA and IgG levels correlated positively with the surrogate neutralization readout. The detectable NELF "receptor-blocking" S1-specific IgA in the first week after diagnosis correlated with a rapid decline in viral load.

Conclusions: Early and intense nasal S1-specific IgA levels link to a rapid decrease in viral load. Our results provide insights into the role of mucosal immunity in SARS-CoV-2 exposure and protection. There may be a role of NELF IgA in the screening and diagnosis of SARS-CoV-2 infection.

Citing Articles

Role of IgA1 protease-producing bacteria in SARS-CoV-2 infection and transmission: a hypothesis.

Russell M, Kilian M, Mestecky J mBio. 2024; 15(10):e0083324.

PMID: 39207101 PMC: 11492985. DOI: 10.1128/mbio.00833-24.

Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals.

Chwa J, Kim M, Lee Y, Cheng W, Shin Y, Jumarang J Viruses. 2024; 16(6).

PMID: 38932145 PMC: 11209246. DOI: 10.3390/v16060852.

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S, Marshall J, Mawer A, Lopez-Ramon R, Harris S, Satti I Lancet Microbe. 2024; 5(7):655-668.

PMID: 38703782 PMC: 7616636. DOI: 10.1016/S2666-5247(24)00025-9.

Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2.

OMahoney C, Watt I, Fiedler S, Devenish S, Srikanth S, Justice E Ann Biomed Eng. 2024; 52(6):1653-1664.

PMID: 38459195 PMC: 11082020. DOI: 10.1007/s10439-024-03478-0.

Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract.

Noh H, Rha M Pathogens. 2024; 13(2).

PMID: 38392851 PMC: 10892713. DOI: 10.3390/pathogens13020113.

References

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Callow K . Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg (Lond). 1985; 95(1):173-89. PMC: 2129501. DOI: 10.1017/s0022172400062410. View

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L . IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2020; 13(577). PMC: 7857408. DOI: 10.1126/scitranslmed.abd2223. View

VanDerMeid K, Su S, Krenzer K, Ward K, Zhang J . A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex. Mol Vis. 2011; 17:1056-63. PMC: 3086627. View

Hansel T, Tunstall T, Trujillo-Torralbo M, Shamji B, Del-Rosario A, Dhariwal J . A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine. 2017; 19:128-138. PMC: 5440599. DOI: 10.1016/j.ebiom.2017.03.033. View

Knop N, Knop E . Conjunctiva-associated lymphoid tissue in the human eye. Invest Ophthalmol Vis Sci. 2000; 41(6):1270-9. View

Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura-Ikeda M, Matsuoka M . Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol. 2021; 93(5):3211-3218. PMC: 8014305. DOI: 10.1002/jmv.26899. View

Ma R, Gan L, Jiang S, Ding P, Chen D, Wu J . High expression of SARS-CoV-2 entry factors in human conjunctival goblet cells. Exp Eye Res. 2021; 205:108501. PMC: 7883706. DOI: 10.1016/j.exer.2021.108501. View

Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P . Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc Natl Acad Sci U S A. 2015; 112(25):7809-14. PMC: 4485102. DOI: 10.1073/pnas.1503885112. View

10.

Chen K, Magri G, Grasset E, Cerutti A . Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat Rev Immunol. 2020; 20(7):427-441. PMC: 10262260. DOI: 10.1038/s41577-019-0261-1. View

11.

Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M . SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020; 26(5):681-687. PMC: 8637938. DOI: 10.1038/s41591-020-0868-6. View

12.

Xu B, Wagner N, Pham L, Magno V, Shan Z, Butcher E . Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. J Exp Med. 2003; 197(10):1255-67. PMC: 2193791. DOI: 10.1084/jem.20010685. View

13.

Steven P, Gebert A . Conjunctiva-associated lymphoid tissue - current knowledge, animal models and experimental prospects. Ophthalmic Res. 2009; 42(1):2-8. DOI: 10.1159/000219678. View

14.

Johansen F, Baekkevold E, Carlsen H, Farstad I, Soler D, Brandtzaeg P . Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood. 2005; 106(2):593-600. DOI: 10.1182/blood-2004-12-4630. View

15.

Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer A, Hanses F . Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. J Clin Virol. 2021; 139:104847. PMC: 8065244. DOI: 10.1016/j.jcv.2021.104847. View

16.

Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A . Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2020; 147(2):545-557.e9. PMC: 7677074. DOI: 10.1016/j.jaci.2020.10.040. View

17.

Kiyono H, Fukuyama S . NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004; 4(9):699-710. PMC: 7097243. DOI: 10.1038/nri1439. View

18.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

19.

Hachim A, Kavian N, Cohen C, Chin A, Chu D, Mok C . ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol. 2020; 21(10):1293-1301. DOI: 10.1038/s41590-020-0773-7. View

20.

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View